Cadila Pharmaceuticals felicitated at ILC for its contribution to leprosy treatment
Ahmedabad: Cadila Pharmaceuticals, one of the largest privately-held pharma companies in the country, was felicitated at the International Leprosy Congress (ILC) in Hyderabad on Thursday.
Cadila Pharmaceuticals was chosen for the honour in recognition of its significant contribution to the cause of leprosy treatment and eradication from India over the years. The company has been working tirelessly and has launched highly-effective drugs to help alleviate the pain and suffering of leprosy-affected persons.
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress, which took place in Hyderabad from November 8 to 11. The Award of Recognition was accepted on behalf of the company by Rajnikant Patel, Sales and Marketing Head, Derma division.
“The International Leprosy Congress is the biggest and most recognized global platform of its kind. Being recognized at the ILC in front of key stakeholders in the field of leprosy from all over the world is a big achievement and speaks volumes about the work Cadila Pharmaceuticals has been doing for the past many years. I extend my sincere gratitude to ILC for this honour and dedicate the award to the entire team at Cadila Pharmaceuticals,” said Jawed Zia, CEO – BSBU, Cadila Pharmaceuticals.
The ILC said that the success story of the reduced burden of leprosy has been achieved due to the development and access to effective leprosy medicines worldwide over the last four decades. It noted that even as physicians, scientists, and leprologists have been responsible for developing key molecules, the pharma industry and leading companies have also contributed significantly by ensuring widespread access to treatment and breakthroughs in treating leprosy.
